Techniques: The application of accelerator mass spectrometry to pharmacology and toxicology

Trends in Pharmacological Sciences

Volumn 25, Issue 8, 2004, Pages 442-447

  White, Ian N H ^a   Brown, Karen ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 3,8 DIMETHYLIMIDAZO[4,5 F]QUINOXALINE; 2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALUMINUM; ATRAZINE; BENZENE; CALCIUM 45; CALCIUM 47; CALCIUM DERIVATIVE; CARBON 14; CARCINOGEN; ISOTOPE; OCHRATOXIN; TAMOXIFEN; TRITIUM;

BIOMEDICINE; CALCIUM TRANSPORT; CHROMATOGRAPHY; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DNA DETERMINATION; DRUG STRUCTURE; HUMAN; IMAGING; INSTRUMENTATION; LIGAND BINDING; MASS SPECTROMETRY; METABOLISM; NONHUMAN; OSTEOPOROSIS; PLASMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY ANALYSIS; TOXICOLOGY; URINALYSIS;

ANIMALS; HUMANS; MASS SPECTROMETRY; PHARMACOKINETICS; PHARMACOLOGY; RADIOISOTOPES; TOXICITY TESTS;

EID: 3242776195     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2004.06.009     Document Type: Review

References (40)

1. Vogel J.S., et al. Accelerator mass spectrometry. Anal. Chem. 67:1995;353A-359A
2. Turteltaub K.W., Vogel J.S. Bioanalytical applications of accelerator mass spectrometry for pharmaceutical research. Curr. Pharm. Des. 6:2000;991-1007
3. 14C via accelerator mass spectrometry. Anal. Chem. 75:2003;2192-2196
4. 3H detection. Nucl. Instrum. Methods Phys. Res. B. 172:2000;40-46
5. Liberman R.G., et al. An interface for direct analysis of C-14 in nonvolatile samples by accelerator mass spectrometry. Anal. Chem. 76:2004;328-334
6. Chiarappa-Zucca M.L., et al. Sample preparation for quantitation of tritium by accelerator mass spectrometry. Anal. Chem. 74:2002;6285-6290
7. 14C accelerator mass spectrometry. Chem. Res. Toxicol. 11:1998;1217-1222
8. Turteltaub K.W., et al. Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. Proc. Natl. Acad. Sci. U. S. A. 87:1990;5288-5292
9. Department of Health (1998) Application for certificate to administer radioactive medicinal products. (http://www.advisorybodies.doh.gov.uk/arsac/ full-app-dec98.pdf).
10. 14C urea breath tests in children. Br. J. Radiol. 75:2002;982-986
11. The European Agency for the Evaluation of Medical Products Evaluation of medicines for Human Use (2002) Position paper on the non-clinical safety studies to support clinical trials with a single low dose of a compound. (CPMP/SWP/2599/02; http://www.emea.eu.int/pdfs/human/swp/259902en.pdf).
12. Lappin G., Garner R.C. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat. Rev. Drug Discov. 2:2003;233-240
13. Combes R.D., et al. Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing. Eur. J. Pharm. Sci. 19:2003;1-11
14. Buchholz B.A., et al. HPLC-accelerator MS measurement of atrazine metabolites in human urine after dermal exposure. Anal. Chem. 71:1999;3519-3525
15. Turteltaub K.W., Dingley K.H. Application of accelerated mass spectrometry (AMS) in DNA adduct quantification and identification. Toxicol. Lett. 102-103:1998;435-439
16. Williams K.E., et al. Attomole detection of in vivo protein targets of benzene in mice: evidence for a highly reactive metabolite. Mol. Cell. Proteomics. 1:2002;885-895
17. Mally A., et al. Ochratoxin A: lack of formation of covalent DNA adducts. Chem. Res. Toxicol. 17:2004;234-242
18. Ohgaki H., et al. Carcinogenicities of heterocyclic amines in cooked food. Mutat. Res. 259:1991;399-410
19. Mauthe R.J., et al. Comparison of DNA-adduct and tissue-available dose levels of MeIQx in human and rodent colon following administration of a very low dose. Int. J. Cancer. 80:1999;539-545
20. Fisher B., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90:1998;1371-1388
21. White I.N.H. Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans. Curr. Drug Metab. 4:2003;223-239
22. Greaves P., et al. Two-year carcinogenicity study of tamoxifen in Alderly Park Wistar-derived rats. Cancer Res. 53:1993;3919-3924
23. 14C] radiolabelled tamoxifen or toremifene to rat DNA using accelerator mass spectrometry. Chem. Biol. Interact. 106:1997;149-160
24. Martin E.A., et al. Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res. 63:2003;8461-8465
25. Boocock D.J., et al. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis. 23:2002;1897-1901
26. 14C-labeled atrazine metabolites in human urine. Anal. Chem. 70:1998;3463-3469
27. 32P-postlabeling. Cancer Res. 59:1999;4829-4833
28. Gamboa da Costa G.G., et al. Quantification of tamoxifen DNA adducts using on-line sample preparation and HPLC-electrospray ionization tandem mass spectrometry. Chem. Res. Toxicol. 16:2003;357-366
29. Hedges R.E.M., et al. Imaging of radiocarbon-labelled tracer molecules in neural tissue using accelerator mass spectrometry. Nature. 383:1996;823-826
30. Jiang Z.X., et al. High resolution AMS imaging of radiocarbon in biomedical applications. Nucl. Instrum. Methods Phys. Res. B. 123:1997;271-274
31. Guerquin-Kern J.L., et al. Ultra-structural cell distribution of the melanoma marker iodobenzamide: improved potentiality of SIMS imaging in life sciences. Biomed. Eng. Online. 3:2004;10
32. Weaver C.M., Liebman M. Biomarkers of bone health appropriate for evaluating functional foods designed to reduce risk of osteoporosis. Br. J. Nutr. 88:(Suppl. 2):2002;S225-S232
33. 41Ca. Bone. 32:2003;. S96 P2 F
34. Priest N.D. The biological behaviour and bioavailability of aluminium in man, with special reference to studies employing aluminium-26 as a tracer: review and study update. J. Environ. Monit. 6:2004;375-403
35. Drueke T.B. Intestinal absorption of aluminium in renal failure. Nephrol. Dial. Transplant. 17:(Suppl. 2):2002;13-16
36. 26Al tracer study. Food Chem. Toxicol. 42:2004;363-371
37. 14C-postlabelling technique using accelerator mass spectrometry for the detection of DNA adducts. Proc Am Assoc Cancer Res. Abstr. 2004;1974
38. 14C-acetic anhydride and accelerator mass spectrometry. Chem. Biol. Interact. 126:2000;171-183
39. Zhou X., Denon P.C. Quantification of strand breaks and abasic sites by accelerator mass spectrometry. Chem. Res Toxicol. 16:2003;1672. Abstr. 49
40. 14C bio-AMS preparation laboratory. Nucl. Instrum. Methods Phys. Res. B. 172:2000;404-408